ICPT - Intercept Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
107.62
+6.09 (+6.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close101.53
Open103.18
Bid0.00 x 1300
Ask0.00 x 800
Day's Range101.87 - 108.00
52 Week Range51.05 - 133.74
Volume300,345
Avg. Volume485,126
Market Cap3.182B
Beta (3Y Monthly)1.71
PE Ratio (TTM)N/A
EPS (TTM)-13.00
Earnings DateOct 30, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est134.60
Trade prices are not sourced from all markets
  • Can This Tiny Biotech Revolutionize a $35 Billion Market?
    Motley Fool10 hours ago

    Can This Tiny Biotech Revolutionize a $35 Billion Market?

    This upstart is developing a diagnostic test and treatment for nonalcoholic steatohepatitis, or NASH, an increasingly common liver disease.

  • Forget Gilead Sciences: Intercept Pharmaceuticals, Inc. Is a Better Growth Stock
    Motley Fool15 hours ago

    Forget Gilead Sciences: Intercept Pharmaceuticals, Inc. Is a Better Growth Stock

    Gilead's high-flying days are seemingly over. Intercept Pharmaceuticals, on the other hand, is only getting started.

  • Why Intercept Pharmaceuticals, Inc. Stock Raced Higher in September
    Motley Fool6 days ago

    Why Intercept Pharmaceuticals, Inc. Stock Raced Higher in September

    Intercept kept rising last month, thanks to Wall Street's change of heart.

  • Analysts Remain Bullish on Intercept Pharmaceuticals
    Market Realist14 days ago

    Analysts Remain Bullish on Intercept Pharmaceuticals

    In October, of the 17 analysts covering Intercept Pharmaceuticals (ICPT), eight have given the stock “buy” or higher ratings, and eight have given it “hold” ratings. One analyst has given Intercept a “sell.” 

  • A Look at Intercept Pharmaceuticals’ Exciting Research Pipeline
    Market Realist14 days ago

    A Look at Intercept Pharmaceuticals’ Exciting Research Pipeline

    Nonalcoholic steatohepatitis (or NASH) focused stocks have been garnering more investor interest so far in 2018. In this series, we’ll analyze three companies with focused NASH pipelines: Intercept Pharmaceuticals (ICPT), Viking Therapeutics (VKTX), and Madrigal Pharmaceuticals (MDGL).

  • GlobeNewswire21 days ago

    Intercept to Present at Upcoming Investor Conference

    NEW YORK, Sept. 26, 2018 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to.

  • What Spark Therapeutics’ Valuation Trend Indicates
    Market Realistlast month

    What Spark Therapeutics’ Valuation Trend Indicates

    Of the 22 analysts covering Spark Therapeutics in September, 11 of them have recommended a “buy” or higher, and nine have recommended a “hold.” Two analysts have given the stock a “sell” or lower rating. The mean rating for Spark stock is 2.41 with a target price of $69.67, implying an upside potential of 18% over its closing price of $59.04 on September 13. Its peers Esperion Therapeutics (ESPR), Intercept Pharmaceuticals (ICPT), and Axovant Sciences (AXON) have mean ratings of 2.27, 2.41, and 2.71, respectively, and target prices of $72.68, $123.07, and $4.70, respectively.

  • Analyzing Axovant Sciences’ Valuation Metrics
    Market Realistlast month

    Analyzing Axovant Sciences’ Valuation Metrics

    In September, there are seven analysts covering Axovant Sciences (AXON) stock. Two of them have given the stock a “buy” rating, and five have given it a “hold.” The mean rating for Axovant stock is 2.71 with a target price of $4.70, implying an upside potential of 129.3% over its trading price of $2.05 on September 11.

  • 3 Top Stocks for Investing in Pharma's Next $35 Billion Market
    Motley Foollast month

    3 Top Stocks for Investing in Pharma's Next $35 Billion Market

    Here's why these three biotechs could come out ahead in the race to tackle a leading cause of liver failure.

  • Here's Why Intercept Pharmaceuticals Jumped 22.7% in August
    Motley Foollast month

    Here's Why Intercept Pharmaceuticals Jumped 22.7% in August

    Its Ocaliva is selling well enough as investors wait for more clinical trial data next year.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Amicus Therapeutics and Intercept Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / September 10, 2018 / Wall Street plunged on Friday after the Trump administration announced tariffs on another $267 billion worth of Chinese goods, pressuring the S&P 500 and ...

  • GlobeNewswire2 months ago

    Intercept to Present at Upcoming Investor Conferences

    NEW YORK, Aug. 29, 2018-- Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, ...

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Array BioPharma and Intercept Pharmaceuticals

    On Friday, Fed Chairman Jerome Powell is scheduled for a speech at the Kansas City Fed’s annual summer retreat. The Nasdaq Composite Index increased 0.49 percent to close at 7,859.17. Investment strategist at Edward Jones, Kate Warne said, “I think that this is optimism on at least some partial resolution of the trade negotiations as investors are expecting progress [on that front].” “If we reach new highs that’s great but I think it would be a reflection of the positive underlying fundamentals of very positive earnings growth and modest interest rates,” Warne added.

  • Array BioPharma Posted Net Loss of $52.4 Million in Q4
    Market Realist2 months ago

    Array BioPharma Posted Net Loss of $52.4 Million in Q4

    On August 14, Array BioPharma (ARRY) announced its fourth quarter and full fiscal 2018 results for the period ended June 30, 2018. The adjusted EPS (earnings per share) for the fourth quarter came in at -$0.17, exceeding analysts’ estimate of -$0.21. Net loss in the fourth quarter of fiscal 2018 was $52.4 million as compared to $29.6 million losses reported in the fourth quarter of fiscal 2017.

  • Is Intercept Pharmaceuticals, Inc. a Buy?
    Motley Fool2 months ago

    Is Intercept Pharmaceuticals, Inc. a Buy?

    This company's leading a race that's drawn a lot of competition.

  • What Analysts Recommend for Array BioPharma Stock
    Market Realist2 months ago

    What Analysts Recommend for Array BioPharma Stock

    Array BioPharma (ARRY) announced its fourth-quarter and full fiscal 2018 results on August 14. That day, ARRY stock registered a decline of ~2.6% and fell further the following day. The decline in stock prices was triggered by the negative investor sentiments due to the Array BioPharma’s fourth-quarter results falling short of estimates. In this article, we’ll look at analysts’ latest recommendations and target prices on ARRY stock over the next 12 months.

  • Puma Biotechnology: Recent Developments and Recommendations
    Market Realist2 months ago

    Puma Biotechnology: Recent Developments and Recommendations

    In June, the Committee for Medicinal Products for Human Use recommended a favorable opinion on the approval of Puma Biotechnology’s (PBYI) Nerlynx for its commercialization in the European Union for the prolonged adjuvant therapy of adults with early-stage HER2+ (hormone-receptor-positive) breast cancer whose prior adjuvant trastuzumab-based therapy is less than one year from completion.

  • How Puma Biotechnology Performed in Q2 2018
    Market Realist2 months ago

    How Puma Biotechnology Performed in Q2 2018

    Puma Biotechnology (PBYI) released its second-quarter earnings results on August 9. It reported net revenue of $117.3 million in the first half of 2018. Puma Biotechnology’s revenue came primarily from its sales of Nerlynx.

  • 2 Growth Stocks That Could Make You Rich
    Motley Fool2 months ago

    2 Growth Stocks That Could Make You Rich

    Heron Therapeutics and Intercept Pharmaceuticals could both produce market-crushing returns for investors over the next decade. Here's why.

  • Intercept Pharmaceuticals’ Stock Price Rose 17.94% on August 6
    Market Realist2 months ago

    Intercept Pharmaceuticals’ Stock Price Rose 17.94% on August 6

    On August 6, Intercept Pharmaceuticals’ (ICPT) stock price grew ~17.94% to $114.71—compared to the previous day’s closing price of $97.26. On August 6, Intercept Pharmaceuticals’ stock price closed at $114.71, which represents ~125% growth from its 52-week low of $51.05 on February 9.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Protagonist Therapeutics and Intercept Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Biotech stocks Protagonist Therapeutics and Intercept Pharmaceuticals were heading higher on Monday after positive developments and analyst upgrades. Protagonist ...

  • Why Intercept Pharmaceuticals Stock Is Moving Higher Today
    Motley Fool2 months ago

    Why Intercept Pharmaceuticals Stock Is Moving Higher Today

    Wall Street is warming up to this mid-cap drugmaker.

  • Barrons.com2 months ago

    Small Biotechs See Big Gains as Bluebird, Intercept Fly

    Smaller biotechs are rising, following the announcement of a collaboration between bluebird bio (BLUE) and Regeneron Pharmaceuticals to tackle cancer and a double upgrade for Intercept Pharmaceuticals (ICPT). Bluebird bio (BLUE) is soaring on news that Regeneron Pharmaceuticals said it would make a $100 million investment in the biotech's stock at $238.10 a share, which represents a 59% premium over bluebird's Friday closing price.  The two companies plan to collaborate on new immune cell therapies for cancer treatment over a period of five years.  Bluebird is up 4.2% to $156.26 in recent trading, while Regeneron is falling 0.6% to $392.42. In addition, Intercept Pharmaceuticals (ICPT) was on the receiving end of a double upgrade from Goldman Sachs.

  • Intercept (ICPT) Gains on Solid Q2 Results, Ocaliva Recovers
    Zacks2 months ago

    Intercept (ICPT) Gains on Solid Q2 Results, Ocaliva Recovers

    Intercept (ICPT) gains on a better-than-expected second quarter as loss narrows and sales surpass estimates on a significant recovery in Ocaliva.

  • Intercept (ICPT) Q2 Loss Narrower-Than-Expected
    Zacks2 months ago

    Intercept (ICPT) Q2 Loss Narrower-Than-Expected

    Intercept (ICPT) reports a narrower-than-expected loss in the second quarter of 2018. Revenues tops expectations.